OraSure Technologies (OSUR) Expected to Announce Quarterly Earnings on Wednesday

OraSure Technologies (NASDAQ:OSUR) will likely be issuing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $28.9610 million for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 5:00 PM ET.

OraSure Technologies Price Performance

Shares of NASDAQ OSUR opened at $2.87 on Wednesday. OraSure Technologies has a one year low of $2.36 and a one year high of $4.60. The business’s fifty day moving average price is $3.16 and its 200-day moving average price is $3.01. The stock has a market capitalization of $209.91 million, a PE ratio of -4.28 and a beta of 0.46.

Institutional Trading of OraSure Technologies

A number of institutional investors have recently added to or reduced their stakes in OSUR. Amundi purchased a new stake in OraSure Technologies during the 1st quarter worth about $47,000. AQR Capital Management LLC raised its holdings in shares of OraSure Technologies by 48.3% in the 1st quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier’s stock valued at $3,511,000 after acquiring an additional 339,493 shares in the last quarter. NewEdge Advisors LLC raised its holdings in shares of OraSure Technologies by 32,595.9% in the 1st quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier’s stock valued at $161,000 after acquiring an additional 47,590 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of OraSure Technologies by 7.2% in the 1st quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier’s stock valued at $1,366,000 after acquiring an additional 27,310 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in shares of OraSure Technologies by 32.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock valued at $99,000 after acquiring an additional 8,133 shares in the last quarter. Hedge funds and other institutional investors own 93.50% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of OraSure Technologies in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $3.00.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.